Diseases and Therapies

🧠 Multiple Sclerosis

Multiple sclerosis is an autoimmune disease that affects the central nervous system, causing inflammation and damage to the myelin sheath of neurons. Symptoms include fatigue, motor changes, sensory and cognitive alterations, directly impacting patients’ quality of life.

💊 Mavenclad® (Cladribine)

Mavenclad is an oral medication used in highly active cases of multiple sclerosis. Its selective action on the immune system provides an effective approach with a simplified dosage.

Estimated cost: R$150,000/year
Justification: Not regularly provided by SUS; high cost and high rate of lawsuits through private insurance.

💊 Leqembi®, Aduhelm®, Kisunla®, Donanemabe

These drugs modulate beta-amyloid plaques in the brain, offering new therapeutic options in early stages of the disease.

Estimated cost: R$250,000/year
Justification: High cost and still under evaluation for incorporation in Brazil; increasing judicial authorization.

🧬 Alzheimer

Alzheimer’s is a progressive neurodegenerative disease that compromises memory, reasoning, and patient autonomy. It’s one of the leading causes of dementia in the elderly, requiring prolonged care and continuous treatment.

🧠 Friedreich’s Ataxia

Friedreich’s Ataxia is a rare and progressive genetic disorder that affects the nervous system and muscles, leading to coordination loss, speech difficulties, and heart problems. It typically appears in adolescence and severely impacts patient autonomy.

💊 Skyclarys® (Omaveloxolone)

Skyclarys is an innovative therapy for Friedreich’s Ataxia. It works on mitochondrial protection and reduces oxidative stress, improving functionality and stabilizing symptoms.

Estimated cost: R$1,500,000/year
Justification: High cost; access only through legal action via insurance; not incorporated in SUS.

💊 Elevidys® (Delandistrogene moxeparvovec)

Elevidys is a one-time gene therapy aiming to restore dystrophin function, a protein essential to muscle health. It’s one of the most promising and expensive modern therapies.

Estimated cost: R$12,000,000
Justification: One-time, ultra-high-cost treatment; access depends solely on legal action.

💪 Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a rare genetic condition that causes progressive muscle degeneration, mainly affecting boys. Symptoms appear in childhood and rapidly impair mobility, breathing, and cardiac function.

🧬 Spinal Muscular Atrophy (SMA)

SMA is a rare genetic disorder affecting motor neurons, which control muscles. It causes progressive weakness and can compromise vital functions like breathing and swallowing, especially in early childhood.

💊 Zolgensma®, Spinraza®, Evrysdi

These medications act directly on the SMN1 gene, essential for motor neuron survival. Zolgensma is a one-time gene therapy; Spinraza and Evrysdi are continuous options with proven results.

Estimated cost: over R$2,000,000
Justification: Extremely high-cost medications, widely litigated successfully; access requires structured legal support.

💊 Tagrisso®, Alecensa®, Enhertu

argeted therapies indicated for patients with specific genetic mutations such as EGFR or ALK. They offer greater survival and quality of life compared to conventional chemotherapy.

Estimated cost: from R$180,000/year
Justification: High cost per patient; not widely incorporated by SUS; access depends on lawsuits or special programs.

🫁 Lung Cancer

Lung cancer is one of the deadliest neoplasms, with early detection being difficult. In advanced stages, it requires targeted therapy and immunotherapy, often not covered by SUS or private insurance.

🧠 Refractory Epilepsy

Refractory epilepsy is marked by seizures that don’t respond adequately to standard medications. It impacts quality of life and cognitive development, especially in children.

💊 Epidiolex® (Canabidiol)

Epidiolex is a CBD-based medication approved internationally for refractory epilepsy, including Dravet and Lennox-Gastaut syndromes.

Estimated cost: over R$1,000/month
Justification: Imported product not available through SUS; well-established judicial access backed by medical reports.

💊 Riluzol, Edaravone

Both drugs support neuronal protection and delay degeneration. Though not curative, they improve life expectancy and quality.

Estimated cost: R$80,000 to R$120,000/year
Justification: Irregular supply by SUS; favorable precedent for lawsuits.

🧠 Amyotrophic Lateral Sclerosis (ALS)

ALS is a degenerative neurological condition that compromises motor neurons, causing progressive paralysis. Its fast progression requires multidisciplinary care and medications to slow it down.

Our Purpose

These are just a few of the diseases and therapies that Phoenix Consultoria helps make accessible every day. Judicial action is one of the most effective tools to ensure the healthcare system or the government fulfills its duty: to deliver the right treatment, at the right time, based on medical prescription and legal backing.

We work with a specialized team, a success rate above 90%, and a transparent process from start to finish. Above all, we believe:

you can’t wait any longer for a broken system.

💬 Ready to take the next step?

If you or someone you love needs high-cost medication or CBD treatment, don’t wait for things to get worse.

📩 Click the button below, tell us your situation, and our team will guide you with personalized and safe assistance.